A b s t r a c t
Primary lymphoma of bone (PLB) is defined as a lymphoma that is confined to the bone or bone marrow. Adult PLB is rare and constitutes fewer than 1% of all non-Hodgkin lymphomas (NHLs). The clinical course is variable, with the survival interval ranging from days to years. [1] [2] [3] [4] [5] [6] [7] The largest series show a 5-year survival of 61%. 5 Almost all cases are subtypes of diffuse large B-cell lymphoma (DLBCL) [3] [4] [5] [6] [7] [8] or its variants, such as T-cell/histiocyte-rich large B-cell lymphomas, 9 with rare cases of peripheral T-cell lymphoma. 2 Many cases have lymphoma cells with centroblastic morphologic features and multilobated nuclei. 5, 7 Approximately 60% of the cases are germinal center B-cell-like (GCB) and are CD10+ or CD10-/bcl-6+/MUM-1-; the remaining cases are post-germinal center or activated B-cell-like (ABC) and are CD10-/bcl-6-or CD10-/bcl-6+/MUM-1+. 7 The absence of CD10 expression in GCB and ABC types correlated with poor prognosis. 7 PLB also occurs in children and constitutes approximately 4% of pediatric NHLs. 10 Pediatric PLBs are more heterogeneous and consist of lymphoblastic lymphoma, Burkitt lymphoma, and diffuse large cell lymphomas. 11, 12 Our previous study indicated that the large cell lymphoma subset of pediatric PLB has a more favorable outcome than the lymphoblastic and Burkitt lymphoma subtypes. 13 Unlike the adult counterpart, the pathology of the large cell subtype of pediatric PLB is poorly characterized. Furthermore, the prognosis of the pediatric subtype is much more favorable, with the largest two series showing a 5-year survival of greater than 95%. 12, 14 The different prognosis suggests that the pediatric and adult large cell subtypes of PLB are distinct entities, the pediatric subtype represents the clinically favorable subset of the adult version, or the pediatric PLB-DLBCL is identical to the adult counterpart and the only difference is the age of the patient. To
Immunohistochemical Analysis
Deparaffinized, 6-µm-thick tissue sections were treated with 3% hydrogen peroxide for 25 minutes, 3% horse serum (Vector Laboratories, Burlingame, CA) for 30 minutes, primary antibody for 30 minutes, biotinylated secondary horse antimouse antibodies (Vector) for 30 minutes, streptavidinbiotin-complex (Vector) for 30 minutes, and diaminobenzidine (DAKO, Carpinteria, CA) for 5 minutes and counterstained with Harris hematoxylin for 15 seconds.
Primary antibodies included those against ALK1, bcl-2, bcl-6, CD3, CD5, CD10, CD20, CD30, CD34, CD45, CD68, CD79a, immunoglobulin light chains κ and λ, Ki-67, MIC2, p53, PAX5, terminal deoxynucleotidyl transferase, and MUM-1 (DAKO). For some antibodies, antigen retrieval was performed using protease digestion or heat. These stains were performed on a Ventana ES automated immunostainer (Ventana Biotek, Tucson, AZ) using a streptavidin-biotin peroxidase detection system. The immunohistochemical stain was considered positive when greater than 25% of the tumor cells were positive.
Results
The clinical characteristics of the 10 cases of PLB-DLBCL were remarkably similar ❚Table 1❚. The patients were all male and in the second decade of life (11-20 years) . Clinical and imaging studies demonstrated the tumor to be confined to bone or direct extension to soft tissue. Five patients had a single focus of involvement, whereas the remainder had multiple foci. All patients responded well to chemotherapy with or without radiotherapy and had no evidence of residual lymphoma after 0.5 to 24 years of follow-up, although 1 patient died of complications of cystic fibrosis. Most patients had bone pain (9/10), occasionally associated with soft tissue swelling (2/10). Most patients were not diagnosed with lymphoma until several months to years after the onset of symptoms (7/10). The histologic sections of the directed bone biopsies shared many morphologic features ❚Table 2❚, ❚Image 1❚, and ❚Image 2❚. In all 10 cases, the tumor cells were paratrabecular or focally replaced the bone marrow and consisted of medium-to large-sized cells with abundant cytoplasm, poorly defined cytoplasmic borders, round to irregular nuclei, dispersed chromatin, and indistinct to small nucleoli. In 8 cases, the tumor cells would be best classified as monomorphic (Image 1A) or pleomorphic (Image 1B) centroblastic cells, whereas 2 cases had multilobated (Image 1C) Other morphologic features included varying levels of necrosis, cytoplasmic retraction (Image 1D), and associated reactive T lymphocytes, neutrophils, and histiocytes. Occasional cases were associated with myeloid hyperplasia that masked the lymphoma cells (Images 2A and 2B). Two cases were noteworthy because of prominent fibrinoid necrosis. In these cases, occasional large, atypical lymphoma cells were present within the fibrinoid necrosis (Images 2C and 2D).
All 10 cases were analyzed by paraffin immunohistochemical analysis ❚Image 3❚ (Table 2 and Image 2). Two cases had limited material and could not be analyzed as extensively as the other 8 cases. All tumor cells marked as mature B cells and were positive for PAX5 (Image 3A), CD20, and CD79a but negative for the immature cell markers terminal deoxynucleotidyl transferase and CD34. In 5 cases, the tumor cells had absent to dim expression of CD45. The fibrinoid necrosis was often reactive to antibodies against CD20 (Image 2D), suggesting that necrosis resulted from tumor necrosis.
We also examined the expressions of CD10, bcl-6, bcl-2, p53, and Ki-67, all considered prognostic markers of PLB-DLBCL or non-bone-based DLBCL. 7, [15] [16] [17] [18] [19] [20] [21] In 7 cases, the tumor cells expressed CD10, consistent with GCBs. The remaining 3 cases had CD10-/bcl-6+ tumor cells that could represent GCBs or ABCs. These 3 cases were each MUM-1-, consistent with GCBs. bcl-2 and p53 were seen in 6 and 3 cases, respectively. Ki-67 staining varied among individual cases (<5% to >75% of the tumor cells), but no case had greater than 90% of the tumor cells stained.
Discussion
Pediatric PLB is an uncommon and heterogeneous collection of distinct NHL subtypes with an overall 5-year eventfree survival of 75% to 100% for localized disease and 25% to 71% for disseminated disease. 14 In the present study, we characterized the morphologic features and immunophenotype of the large cell lymphoma subtype and demonstrated them to be PLB-DLBCL consisting of morphologically unusual centroblastic cells that lacked the typical perimembranous nucleoli.
Our patient population and outcomes were extremely homogeneous. All were males with disease diagnosed in the second decade of life, and all responded well to treatment with no evidence of active disease (NED) at the most recent followup. Our cases are similar to previously reported cases ❚Table 3❚ 3, 4, 7, 11, 12, 14, [22] [23] [24] [25] and ❚Table 4❚, in which pediatric PLB of the large cell type generally occurred in 11-to 20-year-old (42/50 [84%]) males (34/50 [68%]) and had a favorable outcome (~84% with NED) with a median follow-up of greater than 5 years. Our percentage of cases with multifocal bone involvement (50%) was similar to that of previous reports (62%).
Many more PLBs have been reported in adults. [1] [2] [3] [4] [5] [6] [7] [8] Similar to the pediatric counterpart, adult PLB-DLBLC has a male predilection (65%). 5 However, the outcome was more variable. In some series, 1,2,6,8 the prognosis was dismal, with death occurring within 1 year, whereas in other series, 3 1  MCB  +  +  2+  -2+  -2+  +  -<5  ----H  2  MCB  2+  2+  2+  ----+  †  2+  >75  NI  --+  H  3  MCB  2+  2+  2+  Dim+  Dim+ -+  F+  2+  25-50  2+  ---H  4  PCB  2+  2+  2+  -F+  -F+  +  +  >75  NI  ---H  5  PCB  2+  2+  2+  -F+  -+  F+  -<5  NI  ---H  6  MCB  2+  2+  2+  -F+  -+  -+  >75  NI  ---H  7  MCB  2+  2+  2+  +  ND  ND  -+  †  F+  <5  ----H  8  ML  2+  2+  +  NI  NI  ND  +  -NI  50  ND  ND  ND  -H  9  PCB  2+  2+  2+  -+  -+  +  2+  50-75  2+  ----10  ML  2+  2+  +  -+  --+  †  -25-50  +  ---H F+, focally positive; H, tumor negative but increased histiocytes; MCB, monomorphic centroblastic; ML, multilobated centroblastic; Morph, morphologic type; ND, not done; NI, not interpretable owing to high background; PCB, pleomorphic centroblastic; +, positive; 2+, strongly positive; -, negative. * All were negative for terminal deoxynucleotidyl transferase and CD30.
† MUM-1 negative.
was similar to pediatric PLBs (74%-90% with NED). In the largest study of 58 adult PLB-DLBCLs, 5 the 5-year overall survival was 61% and the progression-free survival was 46%, suggesting that overall, patients with pediatric PLBs have a more favorable course. A similar outcome difference is seen between pediatric and adult non-bone-based DLBCLs. 26 Given the variable outcome in adult PLB-DLBCL, 2 large studies have examined the various morphologic features of the lymphoma cells and their prognosis. 5, 7 Approximately equal numbers of cases consisted of multilobated centroblasts (37%-49%) and monomorphic or pleomorphic centroblasts (33%-56%), whereas a small number consisted of immunoblasts (4%-18%). The latter had a statistically significant poorer prognosis compared with the other subtypes. 5 In contrast with the adult counterpart, our pediatric PLB-DLBCL cases had lymphoma cells with monomorphic or pleomorphic morphologic features (80%) and, less commonly, multilobated centroblasts (20%); no case had immunoblastic morphologic features. Details on 2 other cases of pediatric PLB-DLBCL can be gleaned from the adult series that included pediatric patients; both cases contained multilobated centroblasts. 7 Hence, the monomorphic and pleomorphic centroblast morphologic types seem to be the most common, followed by the multilobated form. The immunoblastic form seems to be absent in pediatric PLB-DLBCL. The relative frequencies of the various morphologic features seen in our cases have not been reported for pediatric PLB-DLBCL. Almost all previous studies have not detailed the morphologic features. The 1 exception reported that all 6 cases of pediatric PLB, large cell subtype, had immunoblastic morphologic features 11 ; however, no microphotographs were presented. All 6 cases responded well to treatment and had NED. Further larger studies are needed to verify the relative frequencies of the different morphologic features and the clinical significance of immunoblastic morphologic features in pediatric PLB-DLBCL. All of our cases of pediatric PLB-DLBCL had unusual centroblastic morphologic features that often lacked the typical multiple nucleoli, morphologic features that have not been previously reported. Further study is needed to determine whether these morphologic features exist in adult PLB-DLBCL and are associated with the favorable outcome of the pediatric counterpart. A complementary study is needed to determine whether typical centroblastic morphologic features exist in pediatric PLB-DLBCL and are associated with the poorer outcome of the adult counterpart. Many of our cases had a background of reactive mixed inflammatory cells, extensive necrosis, and/or myeloid hyperplasia that masked the large lymphoma cells. The latter has been previously reported in some adult PLB-DLBCL. 11 This background and the unusual centroblastic morphologic features, resembling histiocytes, have led to misdiagnosis. For example, case 3 was initially seen before the routine use of paraffin immunohistochemical analysis and was diagnosed as "necrosis with acute and chronic inflammation, favor infectious etiology." This diagnosis was confirmed by multiple consultants. The patient was treated with various antibiotics without success. A repeated biopsy 6 months later showed the same morphologic features and received the same diagnosis. Three years after the initial examination, a lymphoma diagnosis was made on a third biopsy that demonstrated sheets of unusual monomorphic centroblasts that marked as B cells. Immunohistochemical analysis of specimens from the previous 2 biopsies showed lymphoma cells within the inflammatory background.
In this patient with 3 years of untreated lymphoma, the initial clinical symptoms clearly represented the onset of lymphoma rather than just its harbinger. This would suggest that other patients with a prolonged history (months to years) of bone pain also had lymphoma at initial examination, suggesting that PLB-DLBCL may have an indolent course.
All of our cases marked as mature B-cell lymphoma and were best classified as DLBCL in the World Health Organization classification, suggesting that almost all pediatric PLBs with large cell morphologic features are likely PLB-DLBCL similar to the adult counterpart. Several immunohistochemical markers predict outcome in adult non-bone-based DLBCL and in adult PLB-DLBCL. Our studies suggest that these markers are less useful predictors in pediatric PLB-DLBCL. In adult PLB-DLBCL, CD10+ lymphomas are associated with a 100% 5-year survival, compared with a 46% 5-year survival in CD10-lymphomas. 7 In contrast, absence of CD10 expression did not seem to be associated with a poor outcome in our pediatric PLB-DLBCLs. The 3 CD10-cases were bcl-6+ and MUM-1-, consistent with GCBs. The GCB phenotype correlates with a favorable outcome in non-bone-based adult DLBCLs. [15] [16] [17] However, in adult PLB-DLBCLs, CD10 expression is a better prognosticator than the GCB vs ABC phenotype. 7 The GCB subtype of the PLB-DLBCLs had an 83% survival rate compared with 75% for the ABC counterpart, a difference that is not statistically significant (P = .224). Furthermore, the GCB vs ABC phenotype has no prognostic significance in pediatric non-bone-based DLBCL, unlike the adult counterpart. 26 Thus, the GCB vs ABC phenotype may not be an accurate predictor of outcome for adult PLB-DLBCL, pediatric PLB-DLBCL, or even pediatric non-bone-based DLBCL. Further larger studies are needed to determine the exact relationship among CD10 expression, GCB phenotype, and clinical outcome in pediatric and adult PLB-DLBCL.
Other poor prognostic markers of DLBCL include high expression of bcl-2, p53, and Ki-67, 18-21 but these seem not to be associated with poor outcome in our cases of pediatric PLB-DLBCL.
We examined the morphologic features and immunophenotype of pediatric PLB-DLBCL to better understand its relationship to the adult counterpart that has a worse prognosis. We anticipated 3 possibilities: (1) The pediatric PLB-DLBCL is identical to the adult counterpart, and the only difference is the age of the patient. (2) The pediatric PLB-DLBCL represents a favorable subtype of the adult counterpart. (3) The pediatric and adult PLB-DLBCLs are distinct entities. We found that the adult and pediatric PLB-DLBCLs differed in their relative frequencies of the morphologic subtypes and in their morphologic features of the nucleoli. Furthermore, the immunophenotype associated with a poor outcome in adult PLB-DLBCLs was not similarly predictive for our cases of pediatric PLB-DLBCL. Our findings favor the last possibility, and further larger studies are needed to validate our findings. NED, no evidence of disease. * Data are given as number (percentage) unless otherwise indicated and are derived from data in Table 3 . For all except NED data, 50 cases were used as the denominator. One study, Suryanarayan et al, 12 did not report large cell subset data separately from data for other subtypes of primary bone lymphomas.
❚Table 3❚ Summary of Previously Reported Cases of Pediatric Primary Bone Lymphomas, Large Cell Subset *
